Alzheimer's Disease Clinical Trials

40 studies are recruiting for alzheimer's disease in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

   The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.

   Stage

   Phase 1

   Ages

   35 to 85

   Site

   K2 Medical Research The Villages LLC, Lady Lake, Florida

   Locations

   26 in total

   Run by

   AC Immune SA

   See if you can join NCT05462106 on ClinicalTrials.gov

2. Low-Dose Radiotherapy for Alzheimer's Disease

   To evaluate the safety and tolerability of low-dose whole brain radiotherapy (WBRT) delivered as an induction course of 0.3 Gy × 10 fractions (3.0 Gy total) followed by 12 months of monthly maintenance LDRT (0.3 Gy × 10 fractions; 3.0 Gy total) in patients with Alzheimer's disease or dementia with …

   Stage

   Phase 1

   Ages

   50 and older

   Site

   Renaissance Institute of Precision Oncology & Radiosurgery, Winter Park, Florida

   Run by

   Evan Thomas

   See if you can join NCT07693140 on ClinicalTrials.gov

3. Crownlands Observing Progression With Neurons Study

   The CROWN-I Study is an observational study to learn about molecular features of Alzheimer's disease (AD) and mild cognitive impairment (MCI). The primary objective is to identify the molecular and genetic modules that differentiate patient subtypes and predict progression of AD. Participants will …

   Stage

   Not phased

   Ages

   55 and older

   Site

   Capital Neurology, Germantown, Maryland

   Run by

   Crownlands

   See if you can join NCT07611396 on ClinicalTrials.gov

4. TREAD: Time Restricted Eating Intervention for Alzheimer's Disease

   The goal of this clinical trial is to learn if restricting the time of eating to allow for prolonged fasting at night may reduce sleep disturbances, cognitive decay, and pathology in patients diagnosed with Mild Cognitive Impairment (MCI) or early to moderate Alzheimer's disease (AD). It will also …

   Stage

   Phase 1

   Ages

   60 and older

   Site

   Shiley Marcos Alzheimer's Disease Center, San Diego, California

   Run by

   University of California, San Diego

   See if you can join NCT06548191 on ClinicalTrials.gov

5. Safety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's Disease

   The present study will administer the drug leronlimab to 20 participants who are above 50 years old with Alzheimer's disease (AD) or mild cognitive impairment (MCI) due to AD. While leronlimab is considered safe in other diseases like Human Immunodeficiency Virus (HIV) and certain types of cancer, …

   Stage

   Phase 2

   Ages

   50 and older

   Site

   Weill Cornell Medicine Brain Health Imaging Institute, New York, New York

   Run by

   Weill Medical College of Cornell University

   See if you can join NCT07553338 on ClinicalTrials.gov

6. A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease

   The primary purpose of this study is to evaluate safety of LEQEMBI in the real-world clinical setting as reported by events of amyloid-related imaging abnormalities (ARIA)-edema (ARIA-E), ARIA-hemosiderin deposition (ARIA-H), symptomatic ARIA-E, symptomatic ARIA-H, and intracerebral hemorrhage (ICH…

   Stage

   Not phased

   Ages

   19 and older

   Site

   Eisai Trial Site #1, Nutley, New Jersey

   Run by

   Eisai Korea Inc.

   See if you can join NCT06810960 on ClinicalTrials.gov

7. Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia

   Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective. Digital biomarkers and blood-based biomarkers will be tested to determine whether a meaningful rel…

   Stage

   Not phased

   Ages

   60 to 90

   Site

   JEM Research Institute, Atlantis, Florida

   Locations

   26 in total

   Run by

   GAP Innovations, PBC

   See if you can join NCT06584357 on ClinicalTrials.gov

8. Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy

   Alzheimer's disease (AD) is characterized by significant memory loss, toxic protein deposits amyloid and tau) in the brain, and changes in the gamma frequency band on EEG. The investigator's lab found that boosting gamma waves in AD mouse models using light and sound stimulation at 40Hz not only re…

   Stage

   Not phased

   Ages

   65 to 100

   Site

   Massachusetts Institute of Technology, Cambridge, Massachusetts

   Run by

   Massachusetts Institute of Technology

   See if you can join NCT05655195 on ClinicalTrials.gov

9. Retinal Imaging in Neurodegenerative Disease

   This study aims to develop and evaluate biomarkers using non-invasive optical coherence tomography (OCT) and OCT angiography (OCTA) as well as ultra-widefield (UWF) fundus photography to assess the structure and function of the retinal and choroidal microvasculature and structure in persons with mi…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Duke University Medical Center, Durham, North Carolina

   Run by

   Duke University

   See if you can join NCT03233646 on ClinicalTrials.gov

10. Open-label Extension Study in Participants With Early Alzheimer's Disease

    The study medicine GSK4527226 is being studied in participants with Alzheimer's Disease (AD) in study 219867 (the parent study, NCT06079190). This new study is an extension of that parent study called an open-label extension (OLE). An OLE is a clinical trial where all participants receive the same …

    Stage

    Phase 2

    Ages

    50 to 85

    Site

    GSK Investigational Site, Maitland, Florida

    Locations

    33 in total

    Run by

    GlaxoSmithKline

    See if you can join NCT07105709 on ClinicalTrials.gov

11. PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases

    The specific aims of the study are: Primary: To determine the presence and regional distribution of microglial activation, as assessed by Fluorine-18 (18F) labeled "Peripheral Benzodiazepine Receptor 06" (PBR06) -PET, in subjects with active Relapsing Remitting Multiple Sclerosis (RRMS), Secondary …

    Stage

    Phase 1

    Ages

    18 to 85

    Site

    Brigham MS Center, 60 Fenwood Road, Boston, Massachusetts

    Run by

    Brigham and Women's Hospital

    See if you can join NCT02649985 on ClinicalTrials.gov

12. Alzheimer's Prevention Registry: A Program to Accelerate Enrollment Into Studies

    The Alzheimer's Prevention Registry (www.endALZnow.org) will collect contact and demographic information on individuals. The objective is to provide information the latest news and advances in Alzheimer's prevention research, and to inform enrollees about research studies in their community. Enroll…

    Stage

    Not phased

    Ages

    18 to 110

    Site

    Banner Alzheimer's Institute, Phoenix, Arizona

    Run by

    Banner Health

    See if you can join NCT02022943 on ClinicalTrials.gov

13. Effect of Physiologic Insulin Administration on Insulin Sensitivity and Cognition

    The goal of this clinical trial is to determine if a weekly delivery of insulin at short intervals lasting up to 2 hours can improve insulin sensitivity and cognition in adults with Alzheimer's Disease. It will also provide information about the safety and feasibility of this intervention. The main…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Pennington Biomedical Research Center, Baton Rouge, Louisiana

    Run by

    Pennington Biomedical Research Center

    See if you can join NCT07265323 on ClinicalTrials.gov

14. A Multi-Modal Combination Intervention to Promote Cognitive Function in Older Intensive Care Unit Survivors

    Up to 25% of intensive care unit (ICU) survivors experience cognitive impairment comparable in severity to mild Alzheimer's disease and related dementias after hospital discharge. Older ICU survivors (ages 60 and older) are at highest risk for delirium and subsequent cognitive impairment, which con…

    Stage

    Not phased

    Ages

    60 and older

    Site

    University of Washington, Seattle, Washington

    Run by

    University of Washington

    See if you can join NCT06411561 on ClinicalTrials.gov

15. Safety and Target Engagement of Centella Asiatica in Cognitive Impairment

    This clinical trial is focused on determining whether biological signatures of target engagement by a Centella asiatica water extract product administered orally for 6 weeks can be measured in comparison to placebo. This study will also assess the safety and tolerability of the Centella asiatica wa…

    Stage

    Phase 1

    Ages

    60 to 85

    Site

    Oregon Health & Science University, Portland, Oregon

    Run by

    Oregon Health and Science University

    See if you can join NCT05591027 on ClinicalTrials.gov